Law­mak­ers push for faster, con­di­tion­al FDA ap­proval path­way for rare dis­ease drugs

As the FDA tight­ens its fo­cus on rare dis­ease treat­ments and speed­ing their en­try to mar­ket, law­mak­ers on Capi­tol Hill are putting se­ri­ous stock in a new ap­proval path­way that would speed new treat­ments for rare dis­eases to pa­tients even faster.

At a hear­ing Thurs­day be­fore the Sen­ate ag­ing com­mit­tee, Sen. Mike Braun (R-IN) tout­ed his Promis­ing Path­way Act, which would es­tab­lish a rolling pri­or­i­ty re­view path­way for drugs to treat life-threat­en­ing dis­eases or con­di­tions. The bill, in­tro­duced in June by a bi­par­ti­san group of sen­a­tors led by Braun and Kirsten Gilli­brand (D-NY), would cre­ate a new way for the FDA to grant time-lim­it­ed pro­vi­sion­al ap­proval to drugs that sub­stan­tial­ly demon­strate ear­ly ev­i­dence of safe­ty and ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER